Rituximab in the treatment of inflammatory myopathies: a review

被引：83

作者：

Fasano, Serena ^{[1
]}

Gordon, Patrick ^{[2
]}

Hajji, Raouf ^{[3
]}

Loyo, Esthela ^{[4
]}

Isenberg, David A. ^{[5
]}

机构：

[1] Univ Naples 2, Dept Clin & Expt Med, Rheumatol Unit, Naples, Italy

[2] Kings Coll Hosp London, Ctr Rheumatol, Dept Med, London, England

[3] Sidi Bouzid Hosp, Fac Sousse, Dept Internal Med, Ibn Aljazzar Med, Sidi Bouzid, Tunisia

[4] Serv Reumatol Inmunol Clin HRUJMCB, Jefe Serv, Santiago, Dominican Rep

[5] UCL, Dept Med, Ctr Rheumatol, London, England

来源：

RHEUMATOLOGY | 2017年 / 56卷 / 01期

关键词：

inflammatory myopathies; dermatomyositis; polymyositis; anti-synthetase syndrome; rituximab; INTERSTITIAL LUNG-DISEASE; ANTI-SYNTHETASE SYNDROME; CELL DEPLETION THERAPY; JUVENILE DERMATOMYOSITIS; REFRACTORY POLYMYOSITIS; RESPIRATORY-FAILURE; MYOSITIS; EFFICACY; PATIENT; ADULT;

D O I：

10.1093/rheumatology/kew146

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in refractory myositis did not show a significant difference between the two treatment groups, and doubts have been expressed about its study design. In this review we present an up-to-date overview of the reported experiences of RTX therapy in myositis. A PubMed search was performed to find all the available cases of refractory myositis patients treated with RTX up to July 2015. The following terms were assessed: inflammatory myopathies OR anti-synthetase syndrome OR polymyositis OR dermatomyositis AND RTX. A total of 48 studies were included. We identified 458 patients with myositis treated with RTX. We found a rate of response to RTX of 78.3%. RTX can play a role in the management of patients with myositis, at least in those with positive myositis-specific autoantibodies.

引用

页码：26 / 36

页数：11

共 50 条

[11] INFLAMMATORY MYOPATHIES - A REVIEW
HEFFNER, RR
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1993, 52 (04): : 339 - 350
[12] Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature
Nalotto, Linda
Iaccarino, Luca
Zen, Margherita
Gatto, Mariele
Borella, Elisabetta
Domenighetti, Marta
Punzi, Leonardo
Doria, Andrea
IMMUNOLOGIC RESEARCH, 2013, 56 (2-3) : 362 - 370
[13] Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature
Linda Nalotto
Luca Iaccarino
Margherita Zen
Mariele Gatto
Elisabetta Borella
Marta Domenighetti
Leonardo Punzi
Andrea Doria
Immunologic Research, 2013, 56 : 362 - 370
[14] Treatment of inflammatory myopathies
Cordeiro, A. C.
Isenberg, D. A.
POSTGRADUATE MEDICAL JOURNAL, 2006, 82 (969) : 417 - 424
[15] TREATMENT OF INFLAMMATORY MYOPATHIES
MASTAGLIA, FL
LAING, BA
ZILKO, P
BAILLIERES CLINICAL NEUROLOGY, 1993, 2 (03): : 717 - 740
[16] Treatment of inflammatory myopathies
Pipitone, Nicolo
Salvarani, Carlo
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (07) : 607 - 621
[17] Treatment of inflammatory myopathies
Mastaglia, FL
Phillips, BA
Zilko, P
MUSCLE & NERVE, 1997, 20 (06) : 651 - 664
[18] Idiopathic inflammatory myopathies—a review
Jonathan Jones
Robert Wortmann
Clinical Rheumatology, 2015, 34 : 839 - 844
[19] Idiopathic inflammatory myopathies: a review
Ashton, Catherine
Paramalingam, Shereen
Stevenson, Brittany
Brusch, Anna
Needham, Merrilee
INTERNAL MEDICINE JOURNAL, 2021, 51 (06) : 845 - 852
[20] Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry
Couderc, Marion
Gottenberg, Jacques-Eric
Mariette, Xavier
Hachulla, Eric
Sibilia, Jean
Fain, Olivier
Hot, Arnaud
Dougados, Maxime
Euller-Ziegler, Liana
Bourgeois, Pierre
Larroche, Claire
Tournadre, Anne
Amoura, Zahir
Mazieres, Bernard
Arlet, Philippe
De Bandt, Michel
Schaeverbeke, Thierry
Soubrier, Martin
RHEUMATOLOGY, 2011, 50 (12) : 2283 - 2289

← 1 2 3 4 5 →